Cornelia L. Dekker, M.D.

Publications

• Adolescent vaccination: recommendations from the National Vaccine Advisory Committee. Stokley S, Freed G, Curtis R, Gordon L, Humiston S, Parnell T, Pavia A, Young A, Johnson D, Kennedy A, Hopfensperger D, Markowitz L, Fergie J, Koslap-Petraco MB, McCauley M. Am J Prev Med. 2009; 36 (3): 278-9.e6
• Differential maternal responses to a newly developed vaccine information pamphlet. Klein NP, Kissner J, Aguirre A, Sparks R, Campbell S, Edwards KM, Dekker CL, Shui I, Gust DA. Vaccine. 2009
• Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults. Keitel WA, Dekker CL, Mink C, Campbell JD, Edwards KM, Patel SM, Ho DY, Talbot HK, Guo K, Noah DL, Hill H. Vaccine. 2009; 27 (47): 6642-8
• One step closer to a CMV vaccine. Dekker CL, Arvin AM. N Engl J Med. 2009; 360 (12): 1250-2
• An algorithm for treatment of patients with hypersensitivity reactions after vaccines. Wood RA, Berger M, Dreskin SC, Setse R, Engler RJ, Dekker CL, Halsey NA. Pediatrics. 2008; 122 (3): e771-7
• Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine. Talbot HK, Keitel W, Cate TR, Treanor J, Campbell J, Brady RC, Graham I, Dekker CL, Ho D, Winokur P, Walter E, Bennet J, Formica N, Hartel G, Skeljo M, Edwards KM. Vaccine. 2008; 26 (32): 4057-61
• Influence of prior influenza vaccination on antibody and B-cell responses. Sasaki S, He XS, Holmes TH, Dekker CL, Kemble GW, Arvin AM, Greenberg HB. PLoS One. 2008; 3 (8): e2975
• Baseline levels of influenza-specific CD4 memory T-cells affect T-cell responses to influenza vaccines. He XS, Holmes TH, Sasaki S, Jaimes MC, Kemble GW, Dekker CL, Arvin AM, Greenberg HB. PLoS One. 2008; 3 (7): e2574
• Mandates for adolescent immunizations: recommendations from the National Vaccine Advisory Committee. Am J Prev Med. 2008; 35 (2): 145-51
• Phenotypic changes in influenza-specific CD8+ T cells after immunization of children and adults with influenza vaccines. He XS, Holmes TH, Mahmood K, Kemble GW, Dekker CL, Arvin AM, Greenberg HB. J Infect Dis. 2008; 197 (6): 803-11
• Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. Bernstein DI, Edwards KM, Dekker CL, Belshe R, Talbot HK, Graham IL, Noah DL, He F, Hill H. J Infect Dis. 2008; 197 (5): 667-75
• The promise and challenge of adolescent immunization. Am J Prev Med. 2008; 35 (2): 152-7
• Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines. Sasaki S, Jaimes MC, Holmes TH, Dekker CL, Mahmood K, Kemble GW, Arvin AM, Greenberg HB. J Virol. 2007; 81 (1): 215-28
• Humoral and cellular immune responses in children given annual immunization with trivalent inactivated influenza vaccine. Zeman AM, Holmes TH, Stamatis S, Tu W, He XS, Bouvier N, Kemble G, Greenberg HB, Lewis DB, Arvin AM, Dekker CL. Pediatr Infect Dis J. 2007; 26 (2): 107-15
• A role for genetics in the immune response to the varicella vaccine. Klein NP, Fireman B, Enright A, Ray P, Black S, Dekker CL. Pediatr Infect Dis J. 2007; 26 (4): 300-5
• Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. He XS, Holmes TH, Zhang C, Mahmood K, Kemble GW, Lewis DB, Dekker CL, Greenberg HB, Arvin AM. J Virol. 2006; 80 (23): 11756-66
• Variability and gender differences in memory T cell immunity to varicella-zoster virus in healthy adults. Klein NP, Holmes TH, Sharp MA, Heineman TC, Schleiss MR, Bernstein DI, Kemble G, Arvin AM, Dekker CL. Vaccine. 2006; 24 (33-34): 5913-8
• Selective developmental defects of cord blood antigen-presenting cell subsets. Drohan L, Harding JJ, Holm B, Cordoba-Tongson E, Dekker CL, Holmes T, Maecker H, Mellins ED. Hum Immunol. 2004; 65 (11): 1356-69
• T cell-dependent production of IFN-gamma by NK cells in response to influenza A virus. He XS, Draghi M, Mahmood K, Holmes TH, Kemble GW, Dekker CL, Arvin AM, Parham P, Greenberg HB. J Clin Invest. 2004; 114 (12): 1812-9
• Persistent and selective deficiency of CD4+ T cell immunity to cytomegalovirus in immunocompetent young children. Tu W, Chen S, Sharp M, Dekker C, Manganello AM, Tongson EC, Maecker HT, Holmes TH, Wang Z, Kemble G, Adler S, Arvin A, Lewis DB. J Immunol. 2004; 172 (5): 3260-7
• Intestinal imaging of children with acute rotavirus gastroenteritis. Bass D, Cordoba E, Dekker C, Schuind A, Cassady C. J Pediatr Gastroenterol Nutr. 2004; 39 (3): 270-4
• Antiviral CD8 T cells in the control of primary human cytomegalovirus infection in early childhood. Chen SF, Tu WW, Sharp MA, Tongson EC, He XS, Greenberg HB, Holmes TH, Wang Z, Kemble G, Manganello AM, Adler SP, Dekker CL, Lewis DB, Arvin AM. J Infect Dis. 2004; 189 (9): 1619-27
• Pediatric uses of valacyclovir, penciclovir and famciclovir. Dekker CL, Prober CG. Pediatr Infect Dis J. 2001; 20 (11): 1079-81
• Antiviral agents effective against herpesviruses. Dekker CL, Prober CG. Curr Clin Top Infect Dis. 2001: 21 271-301
• Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. Corey L, Langenberg AG, Ashley R, Sekulovich RE, Izu AE, Douglas JM, Handsfield HH, Warren T, Marr L, Tyring S, DiCarlo R, Adimora AA, Leone P, Dekker CL, Burke RL, Leong WP, Straus SE. JAMA. 1999; 282 (4): 331-40
• Safety and immunogenicity of Chiron/Biocine recombinant acellular pertussis-diphtheria-tetanus vaccine in infants and toddlers. Black SB, Shinefield HR, Bergen R, Hart C, Kremers R, Lavetter A, Lemesurier J, Morozumi PA, Ray P, Lewis EM, Fireman B, Schwalbe J, Hallam P, Shandling M, Dekker C, Granoff DM, Izu A, Podda A. Pediatr Infect Dis J. 1997; 16 (1): 53-8
• Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial. Straus SE, Wald A, Kost RG, McKenzie R, Langenberg AG, Hohman P, Lekstrom J, Cox E, Nakamura M, Sekulovich R, Izu A, Dekker C, Corey L. J Infect Dis. 1997; 176 (5): 1129-34
• Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group. Keefer MC, Graham BS, McElrath MJ, Matthews TJ, Stablein DM, Corey L, Wright PF, Lawrence D, Fast PE, Weinhold K, Hsieh RH, Chernoff D, Dekker C, Dolin R. AIDS Res Hum Retroviruses. 1996; 12 (8): 683-93
• A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity [corrected] Langenberg AG, Burke RL, Adair SF, Sekulovich R, Tigges M, Dekker CL, Corey L. Ann Intern Med. 1995; 122 (12): 889-98
• Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers. Kahn JO, Sinangil F, Baenziger J, Murcar N, Wynne D, Coleman RL, Steimer KS, Dekker CL, Chernoff D. J Infect Dis. 1994; 170 (5): 1288-91
• Pilot evaluation of influenza virus vaccine (IVV) combined with adjuvant. Keitel W, Couch R, Bond N, Adair S, Van Nest G, Dekker C. Vaccine. 1993; 11 (9): 909-13
• Unrecognized pertussis infection in adolescents. Cromer BA, Goydos J, Hackell J, Mezzatesta J, Dekker C, Mortimer EA. Am J Dis Child. 1993; 147 (5): 575-7
• Comparison of acellular and whole-cell pertussis-component DTP vaccines. A multicenter double-blind study in 4- to 6-year-old children. Morgan CM, Blumberg DA, Cherry JD, Reisinger KS, Blatter MM, Blumer JL, Dekker CL, Stout MG, Christenson PD. Am J Dis Child. 1990; 144 (1): 41-5
• Protective efficacy of the Takeda acellular pertussis vaccine combined with diphtheria and tetanus toxoids following household exposure of Japanese children. Mortimer EA, Kimura M, Cherry JD, Kuno-Sakai H, Stout MG, Dekker CL, Hayashi R, Miyamoto Y, Scott JV, Aoyama T. Am J Dis Child. 1990; 144 (8): 899-904
• Comparison of an acellular pertussis-component diphtheria-tetanus-pertussis (DTP) vaccine with a whole-cell pertussis-component DTP vaccine in 17- to 24-month-old children, with measurement of 69-kilodalton outer membrane protein antibody. Blumberg DA, Mink CM, Cherry JD, Reisinger KS, Blatter MM, Congeni BL, Dekker CL, Stout MG, Mezzatesta JR, Scott JV. J Pediatr. 1990; 117 (1 Pt 1): 46-51
• In vitro sensitivity to acyclovir in genital herpes simplex viruses from acyclovir-treated patients. McLaren C, Corey L, Dekket C, Barry DW. J Infect Dis. 1983; 148 (5): 868-75
• Virus resistance in clinical practice. Dekker C, Ellis MN, McLaren C, Hunter G, Rogers J, Barry DW. J Antimicrob Chemother. 1983: 12 Suppl B 137-52
• Ocular lesions in mice following intracerebral injection of herpes simplex virus type I. Peiffer RL, Dekker CD, Siegel FL. Invest Ophthalmol Vis Sci. 1983; 24 (8): 1070-8